Attapulgite
This article was originally published in The Tan Sheet
Executive Summary
NDMA is scheduled to meet with FDA on July 1 to discuss a recommendation made by FDA's OTC and Gastrointestinal Drugs Advisory Committees on April 9 that attapulgite efficacy in treating diarrhea in adults is unproven ("The Tan Sheet" April 12, p. 1). NDMA expects to review some of the studies presented at the advisory committee meeting and to address follow-up issues and concerns.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning